Eli Lilly and Company

LLYD.BA·Buenos Aires
Compare
27.17+0.34 (+1.27%)today
At close: Nov 4, 5:45 PM ART · May be delayed up to 15 min · USD

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close26.83
Open27.30
Day range26.8327.52
52-week range15.8127.52
Off day high−1.27%
Off 52-week high−1.27%
Volume4.23K
Avg. volume (3M)4.80K
Market cap—
EPS (TTM)—
Forward P/E—
P/E ratio (TTM)—
Dividend yield24.93% (6.69)
Beta (5Y)0.39
Shares outstanding—
Short interest—
Earnings dateAug 7, 2025
Analyst target—
Profit margin31.90%

Against its peers

Compare in full ›
LLYD.BA BIIB BMY GUD.TO 002038.SZ 068270.KS
Market cap — 37.61B 131.21B 1.11B 5.37B 49.02T
P/E (TTM) — 110.2 14.2 75.3 — —
Forward P/E — 15.6 9.6 43.5 — —
Price/book 18.2 2.0 5.6 1.4 1.1 —
Dividend yield 24.93% — 3.93% — 0.19% 0.36%
1-year change +60.67% +62.35% +37.66% +86.16% −31.88% +20.07%
Today +1.27% +2.22% +4.02% +0.36% +1.55% +7.50%

The closest companies by business. Prices may be delayed up to 20 min.

Latest news

All LLYD.BA news ›
Seeking Alpha·Positive

Eli Lilly: Higher Volume, Lower Realized Prices

Pharmaceutical company Eli Lilly and Company (LLY) reported volume growth of 53% last quarter against a 15% decline in realized prices. Revenue rose 39%. Gross margin went up year-over-year, too. That combination is unusual Best Stocks Now…

Trefis·Negative

Is Eli Lilly Stock Increasing Your Market Risk?

Eli Lilly Stock Has Barely Followed The Market No, not over the past year. Between October 31, 2025, and November 3, 2026, the S&P 500 lost 0.606% on the average day it fell, while a $10,000 holding of Lilly stock gained about $15.70. On…

Trefis·

The One Thing To Settle Before Buying Eli Lilly Stock

Eli Lilly (LLY) is selling far more of two drugs, Mounjaro and Zepbound, than it did a year ago. The price the company collects in the U.S., however, is falling. For anyone who owns the stock, the depth of that decline is not settled. This…

Seeking Alpha·Negative

Eli Lilly: Priced For Acceleration, Reporting Deceleration

Eli Lilly delivered strong Q3 results, but underlying growth slowed from 49% to 35% and price erosion deepened. Read more on LLY stock here. - Eli Lilly delivered strong Q3 results, but underlying growth slowed from 49% to 35% and price…

From the 4Search news index, newest first.

In the news

366mentions in 30 days
366with it in the headline
Positivesentiment

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance